Improved overall survival following tyrosine kinase inhibitor (TKI) treatment in NSCLC-are we making progress?
作者信息
Fenchel Klaus, Dale Stephen P, Dempke Wolfram C M
机构信息
Medical School Hamburg (MSH), Hamburg, and Praxisklinik Saalfeld/Saale, Germany ;
Kyowa Kirin Pharmaceutical Development Ltd, Galashiels, UK ;
出版信息
Transl Lung Cancer Res. 2016 Aug;5(4):373-6. doi: 10.21037/tlcr.2016.07.01.
Abstract
摘要
相似文献
1
Improved overall survival following tyrosine kinase inhibitor (TKI) treatment in NSCLC-are we making progress?非小细胞肺癌（NSCLC）患者接受酪氨酸激酶抑制剂（TKI）治疗后总生存期改善——我们正在取得进展吗？
Transl Lung Cancer Res. 2016 Aug;5(4):373-6. doi: 10.21037/tlcr.2016.07.01.
2
Protein tyrosine kinase 2: a novel therapeutic target to overcome acquired EGFR-TKI resistance in non-small cell lung cancer.蛋白酪氨酸激酶 2：克服非小细胞肺癌获得性 EGFR-TKI 耐药的新治疗靶点。
Respir Res. 2019 Dec 2;20(1):270. doi: 10.1186/s12931-019-1244-2.
3
Local Consolidation Therapy (LCT) After First Line Tyrosine Kinase Inhibitor (TKI) for Patients With EGFR Mutant Metastatic Non-small-cell Lung Cancer (NSCLC).一线表皮生长因子受体酪氨酸激酶抑制剂（TKI）治疗后局部巩固治疗用于表皮生长因子受体突变型转移性非小细胞肺癌（NSCLC）患者。
Clin Lung Cancer. 2019 Jan;20(1):43-47. doi: 10.1016/j.cllc.2018.09.015. Epub 2018 Sep 24.
4
Neoadjuvant and adjuvant epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) therapy for lung cancer.肺癌的新辅助和辅助表皮生长因子受体酪氨酸激酶抑制剂（EGFR-TKI）治疗。
Transl Lung Cancer Res. 2015 Feb;4(1):82-93. doi: 10.3978/j.issn.2218-6751.2014.11.08.
5
Activity of EGFR Tyrosine Kinase Inhibitors in NSCLC With Refractory Leptomeningeal Metastases.EGFR 酪氨酸激酶抑制剂在难治性脑膜转移 NSCLC 中的活性。
J Thorac Oncol. 2019 Aug;14(8):1400-1407. doi: 10.1016/j.jtho.2019.05.007. Epub 2019 May 18.
6
Traditional Chinese Medicine Prolongs Progression-Free Survival and Enhances Therapeutic Effects in Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI)Treated Non-Small-Cell Lung Cancer (NSCLC) Patients Harboring EGFR Mutations.中药延长表皮生长因子受体酪氨酸激酶抑制剂（EGFR-TKI）治疗携带 EGFR 突变的非小细胞肺癌（NSCLC）患者无进展生存期并增强治疗效果。
Med Sci Monit. 2019 Nov 9;25:8430-8437. doi: 10.12659/MSM.917251.
7
Posttranslational modifications of FOXO1 regulate epidermal growth factor receptor tyrosine kinase inhibitor resistance for non-small cell lung cancer cells.FOXO1的翻译后修饰调节非小细胞肺癌细胞对表皮生长因子受体酪氨酸激酶抑制剂的耐药性。
Tumour Biol. 2015 Jul;36(7):5485-95. doi: 10.1007/s13277-015-3215-7. Epub 2015 Jun 3.
8
EGFR-tyrosine kinase inhibitor treatment beyond progression in long-term Caucasian responders to erlotinib in advanced non-small cell lung cancer: a case-control study of overall survival.表皮生长因子受体酪氨酸激酶抑制剂治疗在厄洛替尼治疗晚期非小细胞肺癌长期高加索反应者中的进展后：一项总生存的病例对照研究。
Lung Cancer. 2013 Jun;80(3):306-12. doi: 10.1016/j.lungcan.2013.02.010. Epub 2013 Mar 11.
9
Dacomitinib in lung cancer: a "lost generation" EGFR tyrosine-kinase inhibitor from a bygone era?达可替尼用于肺癌治疗：来自过去时代的“失落一代”表皮生长因子受体酪氨酸激酶抑制剂？
Drug Des Devel Ther. 2015 Oct 15;9:5641-53. doi: 10.2147/DDDT.S52787. eCollection 2015.
10
Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer.治疗前表皮生长因子受体 (EGFR) T790M 突变可预测非小细胞肺癌患者对 EGFR 酪氨酸激酶抑制剂反应持续时间更短。
J Clin Oncol. 2012 Feb 1;30(4):433-40. doi: 10.1200/JCO.2011.38.3224. Epub 2012 Jan 3.
引用本文的文献
1
First-Generation EGFR-TKI Plus Chemotherapy Versus EGFR-TKI Alone as First-Line Treatment in Advanced NSCLC With EGFR Activating Mutation: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.第一代表皮生长因子受体酪氨酸激酶抑制剂联合化疗与单纯表皮生长因子受体酪氨酸激酶抑制剂作为伴有表皮生长因子受体激活突变的晚期非小细胞肺癌一线治疗的比较：一项随机对照试验的系统评价和荟萃分析
Front Oncol. 2021 Apr 13;11:598265. doi: 10.3389/fonc.2021.598265. eCollection 2021.
2
Looking for the high way in EGFR-positive non-small cell lung cancer through the evaluation of survival endpoints.通过评估生存终点寻找表皮生长因子受体（EGFR）阳性非小细胞肺癌的治疗新途径
Transl Lung Cancer Res. 2019 Dec;8(Suppl 4):S334-S338. doi: 10.21037/tlcr.2019.06.04.
3
Traveling With Cancer: A Guide for Oncologists in the Modern World.与癌症同行：现代世界肿瘤学家指南
J Glob Oncol. 2019 Jul;5:1-10. doi: 10.1200/JGO.19.00029.
本文引用的文献
1
Challenges and Strategies in Precision Medicine for Non-Small-Cell Lung Cancer.非小细胞肺癌精准医学中的挑战与策略
Curr Pharm Des. 2016;22(28):4374-85. doi: 10.2174/1381612822666160603014932.
2
The coexistence of MET over-expression and an EGFR T790M mutation is related to acquired resistance to EGFR tyrosine kinase inhibitors in advanced non-small cell lung cancer.MET过表达与EGFR T790M突变共存与晚期非小细胞肺癌对EGFR酪氨酸激酶抑制剂的获得性耐药有关。
Oncotarget. 2016 Aug 9;7(32):51311-51319. doi: 10.18632/oncotarget.9697.
3
Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial.阿法替尼对比吉非替尼用于治疗表皮生长因子受体突变阳性的非小细胞肺癌患者的一线治疗（LUX-Lung 7）：一项 2B 期、开放标签、随机对照临床试验。
Lancet Oncol. 2016 May;17(5):577-89. doi: 10.1016/S1470-2045(16)30033-X. Epub 2016 Apr 12.
4
Overall survival in non-small cell lung cancer-what is clinically meaningful?非小细胞肺癌的总生存期——什么才具有临床意义？
Transl Lung Cancer Res. 2016 Feb;5(1):115-9. doi: 10.3978/j.issn.2218-6751.2016.01.06.
5
Immunotherapies for NSCLC: Are We Cutting the Gordian Helix?非小细胞肺癌的免疫疗法：我们正在解开戈尔迪之螺旋吗？
Anticancer Res. 2015 Nov;35(11):5745-57.
6
Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial.阿法替尼对比厄洛替尼二线治疗晚期肺鳞癌患者（LUX-Lung 8）：一项开放标签、随机对照、III 期临床研究。
Lancet Oncol. 2015 Aug;16(8):897-907. doi: 10.1016/S1470-2045(15)00006-6. Epub 2015 Jul 5.
7
Targeted Therapy for NSCLC--A Double-edged Sword?非小细胞肺癌的靶向治疗——一把双刃剑？
Anticancer Res. 2015 May;35(5):2503-12.
8
Impact of Specific Epidermal Growth Factor Receptor (EGFR) Mutations and Clinical Characteristics on Outcomes After Treatment With EGFR Tyrosine Kinase Inhibitors Versus Chemotherapy in EGFR-Mutant Lung Cancer: A Meta-Analysis.表皮生长因子受体（EGFR）特定突变与临床特征对 EGFR 突变型肺癌患者接受 EGFR 酪氨酸激酶抑制剂与化疗治疗后结局的影响：一项荟萃分析。
J Clin Oncol. 2015 Jun 10;33(17):1958-65. doi: 10.1200/JCO.2014.58.1736. Epub 2015 Apr 20.
9
Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials.阿法替尼对比基于顺铂的化疗用于 EGFR 突变阳性肺腺癌（LUX-Lung 3 和 LUX-Lung 6）：两项随机、III 期临床试验总生存数据的分析。
Lancet Oncol. 2015 Feb;16(2):141-51. doi: 10.1016/S1470-2045(14)71173-8. Epub 2015 Jan 12.
10
Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial.多西他赛联合尼达尼布对比多西他赛联合安慰剂治疗既往治疗的非小细胞肺癌（LUME-Lung 1）：一项 III 期、双盲、随机对照试验。
Lancet Oncol. 2014 Feb;15(2):143-55. doi: 10.1016/S1470-2045(13)70586-2. Epub 2014 Jan 9.
Zotero 插件